Clinical Trial Finder

Inclusion Criteria:

• - Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment.

• - Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

• - HLA-A*02:01 positive.

• - Measurable disease according to RECIST 1.1.

• - Adequate selected organ function per protocol.

• - Patient's tumor must express tumor antigen by "IMADetect® RT-qPCR.

• - Life expectancy more than 5 months.

• - Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA203/IMA203CD8.

• - Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA203/IMA203CD8.

• - The patient must have recovered from any side effects of prior therapy to Grade 1 or lower prior to lymphodepletion.

Exclusion Criteria:

• - History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years.

• - Pregnant or breastfeeding.

• - Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents.

• - History of cardiac conditions as per protocol.

• - Prior stem cell transplantation or solid organ transplantation.

• - Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study.

• - History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician.

• - Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.

• - Patients with LDH greater than 2.0-fold ULN.

• - Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or IMA203/IMA203CD8 treatment.

• - Patients with active brain metastases.

• - Concurrent treatment in another clinical trial.

• - For nivolumab treatment, patients must not have a history of severe immune-related toxicities, defined as any Grade 3 or 4 toxicities related to prior PD1/PD-L1 inhibitor therapy (e.g., atezolizumab, pembrolizumab or nivolumab etc.).

Other protocol defined inclusion/exclusion criteria could apply

SCREENING: Patient eligibility will be determined by protocol inclusion/exclusion criteria including HLA (human leukocyte antigen) screening and a biopsy (or collection of archival tumor tissue) for biomarker screening. If the patient is eligible, white blood cells will be taken during leukapheresis for the manufacture of an IMA203 or an IMA203CD8 product. MANUFACTURING: IMA203 or IMA203CD8 products will be made from the patients' white blood cells. TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days before the IMA203/IMA203CD8 product infusion to improve the duration of time that IMA203/IMA203CD8 product stays in the body. The patient will be admitted to the hospital during the T-cell infusion. After the IMA203/IMA203CD8 product infusion, if applicable, a low dose of IL-2 will be given subcutaneously until day 10. In Extension Cohort B (IMA203) nivolumab will be administered intravenously. Patients will be monitored closely throughout the study. The follow-up phase ends 5 years post infusion.

Arms

Experimental: Dose Escalation A

Dose escalation of IMA203

Experimental: Extension Cohort A

IMA203 at RP2D

Experimental: Extension Cohort B

IMA203 at RP2D + nivolumab

Experimental: Extension Cohort AA

IMA203 at anticipated final RP2D (flat dose)

Experimental: Dose Escalation B

Dose escalation of IMA203CD8

Experimental: Extension Cohort C

IMA203CD8 at dose levels confirmed to be safe

Experimental: Extension Cohort D

IMA203CD8 at dose levels confirmed to be safe; without IL-2

Experimental: Ovarian/Uterine

IMA203CD8 monotherapy at dose levels confirmed to be safe

Experimental: Synovial Sarcoma

IMA203CD8 monotherapy at dose levels confirmed to be safe

Experimental: Head and Neck, Lung, and Triple Negative Breast Cancer

IMA203CD8 monotherapy at dose levels confirmed to be safe

Interventions

Biological: - IMA203 Product

The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

Biological: - IMA203 product- flat dose

The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells

Biological: - IMA203CD8 Product

The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

Drug: - nivolumab (Opdivo®)

Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.

Device: - IMADetect®

IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics